Literature DB >> 21894588

[ICU delirium: Consequences for management of analgesia and sedation in the critically ill].

Alawi Lütz, Claudia Spies.   

Abstract

Monitoring and protocolized management for analgesia, sedation and delirium are key indicators for an evidence-based treatment of critically ill patients. Through the dissemination of these guidelines in 2006, use of monitoring was shown to have improved from 8 to 51% and the use of protocol-based approaches increased to 46% (from 21%). From 2006-2009, the existing guidelines from the DGAI (Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin) and DIVI (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin) were developed into 3rd Generation Guidelines for the securing and optimization of quality of analgesia, sedation and delirium management in the intensive care unit (ICU). In collaboration with another 10 professional societies, the literature has been reviewed using the criteria of the Oxford Center of Evidence Based Medicine. Using data from 671 reference works, text, diagrams and recommendations were drawn up. The new 3rd Generation Guideline now includes evidence and consensus-based recommendations for the management of delirium in the intensive care unit. © Georg Thieme Verlag Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21894588     DOI: 10.1055/s-0031-1286607

Source DB:  PubMed          Journal:  Anasthesiol Intensivmed Notfallmed Schmerzther        ISSN: 0939-2661            Impact factor:   0.698


  2 in total

Review 1.  [Delirium in the intensive care unit : Overview for nurses and physicians].

Authors:  A Luetz; B Weiss; H Held; C D Spies
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-04-14       Impact factor: 0.840

2.  Quality of clinical practice guidelines in delirium: a systematic appraisal.

Authors:  Shirley H Bush; Katie L Marchington; Meera Agar; Daniel H J Davis; Lindsey Sikora; Tammy W Y Tsang
Journal:  BMJ Open       Date:  2017-03-10       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.